Cited by 358Protein Degradation and InhibitorsCancer-related Molecular PathwaysUbiquitin and proteasome pathways

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

Open access

Hines, John, Lartigue, Schan, Dong, Hanqing, Qian, Yimin, Crews, Craig M.·2019·Cancer Research

DOI 10.1158/0008-5472.can-18-2918PMC PMC6318015

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Although the number of proteins effectively targeted for posttranslational degradation by PROTAC has grown steadily, the number of E3 ligases successfully exploited to accomplish this has been limited to the few for which small-molecule ligands have been discovered. Although the E3 ligase MDM2 is bound by the nutlin class of small-molecule ligands, there are few nutlin-based PROTAC. Because a nutlin-based PROTAC should both knockdown its target protein and upregulate the tumor suppressor p53, we examined the ability of such a PROTAC to decrease cancer cell viability. A nutlin-based, BRD4-degrading PROTAC, A1874, was able to degrade its target protein by 98% with nanomolar potency. Given the complementary ability of A1874 to stabilize p53, we discovered that the nutlin-based PROTAC was more effective in inhibiting proliferation of many cancer cell lines with wild-type p53 than was a corresponding VHL-utilizing PROTAC with similar potency and efficacy to degrade BRD4. This is the first report of a PROTAC in which the E3 ligase ligand and targeting warhead combine to exert a synergistic antiproliferative effect. Our study highlights the untapped potential that may be unlocked by expanding the repertoire of E3 ligases that can be recruited by PROTAC. Significance: These findings present the first BRD4-targeting MDM2-based PROTAC that possesses potent, distinct, and synergistic biological activities associated with both ends of this heterobifunctional molecule.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-18-2918

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citation
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Ubiquitin ligases: structure, function, and regulation
Zheng, N., & Shabek, N. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014922 · Cited by 1,499
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citation
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Self-citation
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115

Show all 56 references

Sorted by citations

Items 201–300 of 358

Targeted β‐catenin ubiquitination and degradation by multifunctional stapled peptides
Wang, X., Dong, L., Cheng, J., Verdine, G. L., Lin, A., & Chu, Q. (2021) · Journal of Peptide Science · doi:10.1002/psc.3389 · Cited by 13
Development of a potent small‐molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation
Ohoka, N., Suzuki, M., Uchida, T., Tsukumo, Y., Yoshida, M., Inoué, T., Ohki, H., & Naito, M. (2022) · Cancer Science · doi:10.1111/cas.15401 · Cited by 13
PROTACs: The Future of Leukemia Therapeutics
Anwar, Z., Ali, M. S., Galvano, A., Perez, A., Mantia, M. L., Bukhari, I., & Świątczak, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851087 · Cited by 13
Targeted protein degradation might present a novel therapeutic approach in the fight against African trypanosomiasis
Danazumi, A. U., Ishmam, I. T., Idris, S., Izert, M. A., Balogun, E. O., & Górna, M. W. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106451 · Cited by 14
Targeted degradation of hexokinase 2 by a novel engineered bispecific chimeric liposome-based Nano-PROTACs for enhancing tumor chemotherapy
Gong, L., Li, S., Sun, J., Liu, R., Wang, J., Wang, S., Zhao, Y., Yan, L., Ji, M., Yang, D., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123651 · Cited by 12
MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3
Smalley, J. P., Cowley, S. M., & Hodgkinson, J. T. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00449 · Cited by 12
Review of the impact of fragment-based drug design on PROTAC degrader discovery
Chen, P., Li, Q., & Lei, X. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117539 · Cited by 13
Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC into a Pan‐Degrader
Feller, F., Weber, H., Miranda, M., Honin, I., Hanl, M., & Hansen, F. K. (2025) · ChemMedChem · doi:10.1002/cmdc.202500035 · Cited by 13
PROTAC: A Novel Technology for Drug Development**
Li, J., & Liu, J. (2020) · ChemistrySelect · doi:10.1002/slct.202003162 · Cited by 13
The Impact of Olive Oil Compounds on the Metabolic Reprogramming of Cutaneous Melanoma Cell Models
Brito, C., Tomás, A., da Silva, S. R. A., Bronze, M. R., Serra, T., & Pojo, M. (2021) · Molecules · doi:10.3390/molecules26020289 · Cited by 12
Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
Liu, L., Shi, L., Wang, Z., Zeng, J., Wang, Y., Xiao, H., & Zhu, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839857 · Cited by 13
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors
Waksal, J. A., & Mascarenhas, J. O. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00671-7 · Cited by 10
PROTAC-Design-Evaluator (PRODE): An Advanced Method for In-Silico PROTAC Design
S, B. G. A., Agrawal, D., Kulkarni, N. M., Vetrivel, R., & Gurram, K. (2024) · ACS Omega · doi:10.1021/acsomega.3c07318 · Cited by 19
Perspectives on the Development of First-in-Class Protein Degraders
Rambacher, K. M., Calabrese, M. F., & Yamaguchi, M. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0033 · Cited by 11
A New In-Silico Approach for PROTAC Design and Quantitative Rationalization of PROTAC mediated Ternary Complex FormationPreprint
S, B. G. A., Kulkarni, N. M., Agrawal, D., Vetrivel, R., & Gurram, K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.11.499663 · Cited by 10
A synthetic KLHL20 ligand to validate CUL3 KLHL20 as a potent E3 ligase for targeted protein degradationPreprint
Farrell, B. M., Gerth, F., Yang, C.-H. R., & Yeh, J. T. ‐. (2022) · Genes & Development · doi:10.1101/gad.349717.122 · Cited by 12
Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets
Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer
Yang, Y., Zhao, C.-J., Jin, Z.-F., Zheng, J., & Ma, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1120828 · Cited by 11
Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines
Hu, J., Yang, J., Zhou, R., Chen, K., Zhao, H., & Zhou, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117159 · Cited by 10
Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
Gu-liang, Y., Zhong, H., Xia, X., Qi, Z., Wang, C., & Li, S. (2021) · Food Science and Human Wellness · doi:10.1016/j.fshw.2021.11.001 · Cited by 10
CRBN ligand expansion for hematopoietic prostaglandin D2 synthase (H-PGDS) targeting PROTAC design and their in vitro ADME profiles
Osawa, H., Kurohara, T., Ito, T., Shibata, N., & Demizu, Y. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117259 · Cited by 10
Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple‐negative breast cancer (TNBC)
Dogheim, G. M., & Amralla, M. T. (2023) · Drug Development Research · doi:10.1002/ddr.22055 · Cited by 11
Cell-Permeable Peptide Inhibitors of the p53-hDM2 Interaction via Foldamer Helix Mimicry and Bis-Thioether Stapling
Neuville, M., Bourgeais, M., Li, B., Varajao, L., Hallé, F., Goudreau, S. R., Thinon, E., Pasco, M., Khatib, A., & Guichard, G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01762 · Cited by 10
Epigenetic targets and their inhibitors in the treatment of idiopathic pulmonary fibrosis
Miao, X., Liu, P., Liu, Y., Zhang, W., Li, C., & Wang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117463 · Cited by 8
Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains
Huang, C., Harris, C. L., Siddiqui, G., & Jörg, M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00726 · Cited by 8
MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell
Yuan, Z., Guo, M., Zhang, Y., Deng, Y., Sun, B., Hou, Y., Wang, X., Jin, X. J., Liu, Y., Shi, B., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02392-1 · Cited by 12
Bromodomain-containing 4 as a therapeutic target in inflammatory bowel diseases and colorectal cancer
Marafini, I., Frascatani, R., Colella, M., Cristofaro, E. D., & Monteleone, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1682223 · Cited by 8
PROTAC: A Novel Drug Delivery Technology for Targeting Proteins in Cancer Cells
Bala, R., Sindhu, R. K., Madaan, R., & Yadav, S. K. (2022) · Current Drug Discovery Technologies · doi:10.2174/1570163820666221031124612 · Cited by 8
A Keap1-recruiting BRD4 degrader offers a single-molecular polypharmacology approach for the treatment of metabolic dysfunction-associated steatohepatitis
Zhang, X., Ge, Y., Ye, M., Wang, X., Tong, Y., Liu, C., Xu, S., Zhao, Z., You, Q., Guo, X., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.02.042 · Cited by 8
PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders
Tomoshige, S., & Ishikawa, M. (2020) · Angewandte Chemie · doi:10.1002/ange.202004746 · Cited by 8
Reviewing the toolbox for degrader development in oncology
Cresser-Brown, J. O., Marsh, G. P., & Maple, H. J. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.009 · Cited by 8
PROTAC Degraders
Ciulli, A., & Hsia, O. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch9 · Cited by 8
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation
Zhao, J., Chen, H., & Liang, C. (2025) · Biomarker Research · doi:10.1186/s40364-025-00826-7 · Cited by 7
A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications
Stacey, P., Lithgow, H., Lewell, X. Q., Konopacka, A., Besley, S., Green, G., Whatling, R., Law, R. P., Röth, S., Sapkota, G. P., et al. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211017517 · Cited by 7
Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins
Yokoo, H., Tsuji, G., Inoué, T., Naito, M., Demizu, Y., & Ohoka, N. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107204 · Cited by 7
Protein-protein interactions: a structural view of inhibition strategies and the IL-23/IL-17 axis
Allen, S. J., & Lumb, K. J. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.12.006 · Cited by 7
Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies
Wu, Y., Zhang, J., Zhu, X., & Zhang, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215808 · Cited by 8
Allyl-isothiocyanate against colorectal cancer via the mutual dependent regulation of p21 and Nrf2
Ren, X., Zhang, G., Ling, X., Zhang, L., Tian, Y., Zhu, G., Wang, P., Leavenworth, J. W., Luo, L., & Li, F. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176016 · Cited by 8
N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances
Banerjee, S., Sharma, S., Thakur, A., Sachdeva, R., Sharma, R., Nepali, K., & Liou, J. (2023) · Current Drug Targets · doi:10.2174/0113894501273969231102095615 · Cited by 7
Subversion of Ras Small GTPases in Cutaneous Melanoma Aggressiveness
Brito, C., Barral, D. C., & Pojo, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.575223 · Cited by 7
From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins
Nagel, Y. A., Britschgi, A., & Ricci, A. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch2 · Cited by 6
PROTAC-Design-Evaluator (PRODE) : An Advanced Method for in-silico PROTAC designPreprint
S, B. G. A., Agrawal, D., Kulkarni, N. M., Vetrivel, R., & Gurram, K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.12.544569 · Cited by 7
The Expanding E3 Ligase-Ligand Landscape for PROTAC Technology
Li, Z., Huang, X., Zhao, X., Zhang, Y., & Li, P. (2025) · Targets · doi:10.3390/targets3040030 · Cited by 9
MYCN in neuroblastoma: The kings' new clothes and drugs
Müller, M., Trunk, K., Fleischhauer, D., & Büchel, G. (2024) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2024.100182 · Cited by 7
Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation
Zhou, Z., Zalutsky, M. R., & Chitneni, S. K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00531 · Cited by 6
Chemical Biology Tools for Protein Lysine Acylation
Xie, Y., Du, S., Liu, Z., Liu, M., Xu, Z., Wang, X., Kee, J. X., Yi, F., Sun, H., & Yao, S. Q. (2022) · Angewandte Chemie · doi:10.1002/ange.202200303 · Cited by 6
Methods to characterize and discover molecular degraders in cells
Lin, Z., & Woo, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00261b · Cited by 7
Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules
Khan, M. Z. I., Nazli, A., Pan, Y., & Chen, J. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220803112409 · Cited by 7
bioPROTACs establish RAS as a degradable target and provide novel RAS biology insightsPreprint
Lim, S., Khoo, R., Juang, Y.-C. A., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.174565 · Cited by 6
A CRISPR activation screen identifies FBXO22 as an E3 ligase supporting targeted protein degradationPreprint
Basu, A. A., Zhang, C., Riha, I. A., Magassa, A., Ko, F., & Zhang, X. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557708 · Cited by 6
Temporal and Spatial Characterization of CUL3 KLHL20 -Driven Targeted Degradation of BET Family BRD Proteins by the Macrocycle-Based Degrader BTR2004
Fechtmeyer, P. H., Martinez, C., & Yeh, J. T. ‐. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00343 · Cited by 5
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
Castagna, D., Gourdet, B., Hjerpe, R., MacFaul, P., Novak, A., Révol, G., Rochette, É., & Jordan, A. M. (2024) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2024.07.002 · Cited by 5
A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2
Liu, Y., Liu, Y., Yang, K., Zhang, Z., Zhang, W., Yang, B., Li, H., & Chen, L. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109264 · Cited by 5
Utilising the intrinsic fluorescence of pomalidomide for imaging applications
Brownsey, D. K., Gafuik, C. J., Kim, D., O’Sullivan, L., Gorobets, E., Krukowski, S., Turk, M., Jenne, C. N., Mahoney, D. J., & Derksen, D. J. (2023) · Chemical Communications · doi:10.1039/d3cc04314b · Cited by 5
Targeting super-enhancer activity for colorectal cancer therapy
Voutsadakis, I. A. (2024) · American Journal of Translational Research · doi:10.62347/qkhb5897 · Cited by 5
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Ambrosini, M., Fucà, G., Duca, M., Damian, S., Santis, F. D., Corti, F., Cresta, S., de Braud, F., & Nicola, M. D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103532 · Cited by 5
PROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
Du, M., Liu, T., Wang, W., Fan, S., Tian, M., Du, Q., Wang, Z., Li, X., Liu, X., Xia, Q., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100332 · Cited by 4
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
Knoll, N., Neamati, N., & Üren, A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00730 · Cited by 5
A Tandem-Affinity Purification Method for Identification of Primary Intracellular Drug-Binding Proteins
Islam, S., Gour, J., Beer, T., Tang, H., Cassel, J. A., Salvino, J. M., & Busino, L. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00570 · Cited by 5
Targeted Management: Unlocking the Crucial Role of PROTACs in Cancer Treatment
Gupta, P., Dutta, S., Kumar, P., Kaushik, M., Ashique, S., & Bhowmick, M. (2025) · Current Drug Discovery Technologies · doi:10.2174/0115701638324854250218053353 · Cited by 5
An updated patent review of EZH2 inhibitors (2024–present)
Wan, G., Li, S., Tang, Q., Qiu, H., Zhang, Q., & Yu, L. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2483399 · Cited by 4
Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer
Lin, L., Zheng, F., Wei, H., Wu, X., Yan, H., & Ding, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118432 · Cited by 4
Targeted degradation of BRD4 by PROTACs: advances in cancer therapy
Hong, Y., Liu, X., Li, Y., Yu, M., Wang, C., Nie, C., & Xu, S. (2026) · Chemical Communications · doi:10.1039/d5cc05563f · Cited by 5
Discovery of a KLHL41 Ligand for Muscle Specific Protein Degradation
Yim, J., Lee, J., Kim, S., Choi, J., Yoon, S., Cho, H., Jung, S., Yoo, G., Lee, S., Park, H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73252-4 · Cited by 5
Cellular functions and molecular mechanisms of ubiquitination in osteosarcoma
Song, J., Yuan, X., Piao, L., Wang, J., Wang, P., Zhuang, M., Liu, J., & Liu, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1072701 · Cited by 5
Advantages and Disadvantages of PROTACs
Pujari, R., Bhatt, S., Soni, U., Sharma, S., & Patil, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_4 · Cited by 4
Hijacking the MDM2 E3 Ligase with Novel BRD4‐Targeting Proteolysis‐Targeting Chimeras in Pancreatic Cancer Cells
Ficu, M. P., Niculescu‐Duvaz, D., Aljarah, M., Kershaw, C. S., & Springer, C. J. (2025) · ChemBioChem · doi:10.1002/cbic.202500133 · Cited by 5
Synthesis of selective BCL-XL PROTAC and potent antitumor activity in glioblastoma
Liu, M., Sun, B., Niu, R., Zhang, Y., Li, X., Wang, J., Wang, X., & Yin, J. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102593 · Cited by 4
PROTACs improve selectivity for targeted proteins
Liu, L., Guan, X., Zhuo, J., Wu, X., & Han, X. (2025) · Acta Materia Medica · doi:10.15212/amm-2025-0015 · Cited by 3
A triple-action PROTAC for wild-type p53 cancer therapy
Bird, G. H., Adhikary, U., Schmidt, M. J., Godes, M., Tesar, B. M., Camara, C. M., Paulo, J. A., Vidlak, J. F., DeAngelo, T. M., Marquez, M., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102467 · Cited by 4
Context matters: E3 ligase–ligand pairing strategies for optimized PROTAC performance
Yin, L., Shu, P., & Peng, X. (2025) · Protein & Cell · doi:10.1093/procel/pwaf107 · Cited by 6
Prospects and advances of PROTAC in the treatment of hematologic malignancies
Wang, X., Zhang, M., & Mei, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00759-3 · Cited by 3
The application of drug delivery systems based on targeted protein degradation chimeras in disease treatment strategies
Lin, W., Qiao, E., Wang, Z., Tang, C., Li, C., & Lu, J. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04372-8 · Cited by 4
Nanopore Discrimination of Protein–Small-Molecule Drug Complexes at Near-Atomic Resolution
Jo, J., Kim, J., Hwang, S., Jeong, K., & Chi, S. (2026) · ACS Nano · doi:10.1021/acsnano.5c22458 · Cited by 3
PROTACs for central nervous system disorders: challenges and opportunities
Zheng, N., Shao, J., Xiong, B., Wei, Y., Wang, X., Zhou, Y., Song, Z., Zhang, A., Xu, C., Zhao, Q., et al. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118703 · Cited by 4
Reengineering of a Proteomimetic Pan‐Ras Inhibitor into a Ras Degrader
Ongkingco, J. F., Hong, S. H., Toth, E. D., Nguyễn, T. T., & Arora, P. S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202507092 · Cited by 4
Pharmacophore-based ML model to filter candidate E3 ligands and predict E3 Ligase binding probabilities
Karki, R., Gadiya, Y., Shetty, S., Gribbon, P. M., & Zaliani, A. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101424 · Cited by 3
Bromodomain and Extraterminal Domain Protein 2 in Multiple Human Diseases
Ji, Y., Chen, W., & Wang, X. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.002036 · Cited by 3
The rise of new targets in melanoma
Bai, X. L., & Flaherty, K. T. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf251 · Cited by 2
Unraveling the secrets of novel PROTACs to improve degradation efficacy
Huang, J., Yang, X., Huang, Q., Gao, Y., Bandaranayake, P. C. G., Kandegama, W. M. W. W., Ashby, C. R., Dong, Y., Wang, Z., & Hao, G. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11273-9 · Cited by 3
Study on the design, synthesis and activity of MDM2/MDMX anti-tumor stapled peptide PROTAC
Liao, X., Guo, M. W., Hu, D., Su, C., & Liao, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-18026-6 · Cited by 2
Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
Hu, L., Wu, S., Wang, W., He, H., Che, J., Wu, M., & Dong, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118499 · Cited by 4
Dual / bifunctional targeting of bromodomain and extra-terminal (BET) proteins: Expanding the paradigm of epigenetic drug discovery
Jiang, F., Li, H., Sun, Q., Huang, J., Chen, X., Liang, Q., Luo, X., Zhang, W., He, D., & Shen, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118524 · Cited by 3
Discovery of a First‐in‐Class Murine Double Minute 2‐Recruiting Positive Transcription Elongation Factor B PROTAC Degrader With Selective Antitumor Activity
Guan, X., Xie, L., Guo, H., Ma, L., Zhou, J., Luo, L., Yang, H., Wu, Y., Liu, J., Wang, Y., et al. (2026) · MedComm · doi:10.1002/mco2.70723 · Cited by 2
Permeability enhancer incorporated oral nanosuspension of ARV-825 PROTAC for Glioblastoma treatment
Patel, H., Yadav, A., Dukhande, V. V., & Patel, K. R. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00771-5 · Cited by 2
Protac: redirecting protein degradation systems to new substrates
Esperón, Á. C., & Villacampa, M. (2022) · Anales de la Real Academia Nacional de Farmacia · doi:10.53519/analesranf.2022.88.01.03 · Cited by 1
The synthesis and characterization of tetramic acid derivatives as Mdm2-p53 inhibitors
Muszak, D., Łabuzek, B., Brela, M. Z., Twarda‐Clapa, A., Czub, M., Musielak, B., Surmiak, E., & Holak, T. A. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.03.089 · Cited by 2
Senolytics Target Senescent Cells and Improve Aging and Age-Related Diseases
Buffard, T., & Ferbeyre, G. (2020) · Healthy ageing and longevity · doi:10.1007/978-3-030-44903-2_4 · Cited by 2
Advances in AR-Targeting Chimeras: A Case Study of proteolysis-targeting Chimeras From Bench to Bedside
Du, W. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0147 · Cited by 2
Targeted Protein Degradation by Proteolysis Targeting Chimeras
Du, W. (2022) · Wiley eBooks · doi:10.1002/9781119627784.ch11 · Cited by 2
Biochemical Principles of Targeted Protein Degradation
Agafonov, R. V., Deibler, R. W., Elam, W. A., Patel, J. S., & Fisher, S. L. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch10 · Cited by 2
KRAS degraders
Jean-Francois, F. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00010-3 · Cited by 1
Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities
Yang, J., Qiao, Q., Lin, N., Niu, M., Su, L., & Yin, B. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70427 · Cited by 2
PROTAC-based protein degradation: a window of opportunity for melanoma therapy
Gentile, G., D’Aguanno, S., Martile, M. D., Petricca, A., Valentini, E., Scalera, S., & Bufalo, D. D. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01225-2 · Cited by 1
PROTAC-Mediated Targeted Degradation of MDM2 Induces Tumor-Suppressive Signaling in Osteosarcoma Cells
Kim, Y., Kim, J. E., Choi, J., Kim, J., Park, S., Choi, W., An, H., Kim, J., Kim, M., Choi, S., et al. (2026) · Cells · doi:10.3390/cells15050473 · Cited by 1
Context matters in PROTAC design: navigating the trade-off between degradation and developability
Zhang, B., Zhang, Y., Zhang, B., Hu, J., Ke, C., Wu, T., Wei, M., Xia, J., Wang, M., Zhao, Q., et al. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2707656 · Cited by 1
Targeted Protein Degradation Chemical Probes
Galdeano, C., & Barril, X. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00150 · Cited by 1
Anticancer Therapy with Proteolysis-targeting Chimeras [PROTACs] Targeting the Tumor-microenvironment: Development, Current State and Prospects
Vanangamudi, M., Kaushik, M., Guptha, P. M., Surendran, V., & Gupta, P. K. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947304955240430124514 · Cited by 1
PROTACs in Treatment of Glioma
Kumar, S., & Maharshi, V. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_15 · Cited by 1
WITHDRAWN: Targeted protein degradation: A promising approach for cancer treatment
Khan, M. Z. I., Nazli, A., Naz, I., Khan, D., Haq, I., & Chen, J. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.09.004 · Cited by 1
Retracted

Authors: Hines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M.
Affiliations: Yale University (US)
Arvinas (United States) (US)
Corresponding author: Crews, Craig M.
ORCID: Qian, Yimin
Crews, Craig M.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2019-01-01
Volume: 79
Issue: 1
Pages: 251-262
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-18-2918
PMC: PMC6318015
OpenAlex: W2898621430
Cited by: 348
References: 56
Citations by year: 2026: 30 · 2025: 49 · 2024: 52 · 2023: 41 · 2022: 60 · 2021: 45 · 2020: 45 · 2019: 25
FWCI: 10.49
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: NCI (R50 CA211252)
NIH (R35 CA197589)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords: PROTACs, MDM2, BRD4 degradation, p53 stabilization, nutlin, E3 ubiquitin ligase, VHL, antiproliferative activity, drug synergy, heterobifunctional molecules, tumor cell proliferation
MeSH terms: Bromodomain Containing Proteins, Drug Synergism, Fibrinolytic Agents, Humans, Neoplasms, Nuclear Proteins, Peptides, Transcription Factors, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Cell Cycle Proteins, Cell Proliferation, Proto-Oncogene Proteins c-mdm2, Protein Stability, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks